O
2.31
-0.07 (-2.94%)
Previous Close | 2.38 |
Open | 2.36 |
Volume | 77,206 |
Avg. Volume (3M) | 96,907 |
Market Cap | 94,176,384 |
Price / Earnings (TTM) | 4.53 |
Price / Sales | 152.49 |
Price / Book | 0.620 |
52 Weeks Range | |
Earnings Date | 7 Nov 2024 |
Diluted EPS (TTM) | 0.110 |
Total Debt/Equity (MRQ) | 0.28% |
Current Ratio (MRQ) | 27.08 |
Operating Cash Flow (TTM) | -7.92 M |
Levered Free Cash Flow (TTM) | -2.41 M |
Return on Assets (TTM) | -4.12% |
Return on Equity (TTM) | 2.89% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Mixed |
Biotechnology (Global) | Mixed | Mixed | |
Stock | Oramed Pharmaceuticals Inc. | Mixed | Mixed |
AIStockmoo Score
-0.8
Analyst Consensus | NA |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | 0.0 |
Technical Oscillators | -0.5 |
Average | -0.83 |
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
% Held by Insiders | 10.62% |
% Held by Institutions | 17.52% |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
07 Oct 2024 | Announcement | Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |